# Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Colombia

> **NCT02851069** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 66 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02851069
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-23
- **Primary completion:** 2018-08-30
- **Final completion:** 2018-08-30
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2019-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02851069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02851069, "Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Colombia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02851069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*